Skip to main content
Premium Trial:

Request an Annual Quote

Exact, OncoMethylome Pen Two-Part Deal to Sell CRC-Screening Tests, Services in Europe, N. America

NEW YORK (GenomeWeb News) — OncoMethylome Sciences and Exact Sciences today said they plan to advance the sale of stool-based colorectal cancer-screening technologies through service labs in Europe and North America. 
 
The agreement calls for Exact to grant OncoMethylome non-exclusive rights to its DNA-stabilization, -isolation, and -extraction technology for stool-based CRC-screening tests in Europe.
 
In exchange, OncoMethylome will pay royalties to Exact based on sales.
 
Separately, OncoMethylome will sell reagents to Exact, which may use them in stool-based CRC screening services in North America.
 
The reagents will enable Exact to detect methylation at certain DNA markers using MSP technology. The terms of the agreement also call for OncoMethylome to sell reagents to Exact’s commercial partners, subject to their negotiation with OncoMethylome.
 
Further financial details of the license and supply agreements were not disclosed. 

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.